Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
Thomas E. Delea, Paul Tappenden, Oleg Sofrygin, Dominy Browning, Mayur M. Amonkar, Jon Karnon, Mel D. Walker and David CameronVolume:
13
Language:
english
Journal:
The European Journal of Health Economics
DOI:
10.2307/23275635
Date:
October, 2012
File:
PDF, 2.24 MB
english, 2012